Translational Research in Gastric Malignancy

Surgical Oncology Clinics of North America

Volumn 17, Issue 2, 2008, Pages 323-340

  Johnson, Sara M ^a   Evers, B Mark ^a,b  

^a University of Texas Medical Branch School of Medicine   (United States)

^b UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CATUMAXOMAB; CETUXIMAB; CISPLATIN; DASATINIB; DNA; ERLOTINIB; GASTROINTESTINAL POLYPEPTIDE; GEFITINIB; GEMTUZUMAB OZOGAMICIN; GROWTH FACTOR; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR; IBRITUMOMAB TIUXETAN; IMATINIB; IRINOTECAN; LAPATINIB; PANITUMUMAB; PROTEIN TYROSINE KINASE; REMOVAB; RITUXIMAB; SORAFENIB; SUNITINIB; TRASTUZUMAB; UNCLASSIFIED DRUG; VORINOSTAT; XL 880;

BACTERIAL INFECTION; CANCER CLASSIFICATION; CANCER DIAGNOSIS; CANCER IMMUNOLOGY; CANCER INHIBITION; CANCER RESEARCH; CANCER THERAPY; CARCINOGENESIS; CLINICAL TRIAL; COLORECTAL CANCER; DEACETYLATION; DNA METHYLATION; DRUG TARGETING; EPIGENETICS; GASTRITIS; HELICOBACTER PYLORI; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; LUNG ADENOCARCINOMA; NONHUMAN; ONCOGENE; OUTCOME ASSESSMENT; PROGNOSIS; PROTO ONCOGENE; REVIEW; RNA TRANSLATION; SIGNAL TRANSDUCTION; SOLID TUMOR; STOMACH CANCER; TREATMENT OUTCOME; TUMOR SUPPRESSOR GENE;

EPIGENESIS, GENETIC; EVIDENCE-BASED MEDICINE; GASTRITIS; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, TUMOR SUPPRESSOR; HELICOBACTER INFECTIONS; HUMANS; ONCOGENES; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; RISK FACTORS; STOMACH NEOPLASMS;

EID: 41149108569     PISSN: 10553207     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.soc.2008.01.001     Document Type: Review

References (75)

1. Crew K.D., and Neugut A.I. Epidemiology of gastric cancer. World J Gastroenterol 12 3 (2006) 354-362
2. Abdalla E., Ahmad S.A., Pearlstone D.B., et al. Gastric cancer. In: Feig B., Berger D.H., and Fuhrman G.M. (Eds). The M.D. Anderson surgical oncology handbook. 3rd edition (2003), Lippincott Williams & Wilkins, Philadelphia
3. Wagner A.D., Schneider P.M., and Fleig W.E. The role of chemotherapy in patients with established gastric cancer. Best Pract Res Clin Gastroenterol 20 4 (2006) 789-799
4. Burkitt M.D., and Pritchard D.M. Review article: pathogenesis and management of gastric carcinoid tumours. Aliment Pharmacol Ther 24 9 (2006) 1305-1320
5. Miettinen M., and Lasota J. Gastrointestinal stromal tumors: review on morphology, molecular pathology, prognosis, and differential diagnosis. Arch Pathol Lab Med 130 10 (2006) 1466-1478
6. Du M.Q., and Atherton J.C. Molecular subtyping of gastric MALT lymphomas: implications for prognosis and management. Gut 55 6 (2006) 886-893
7. Ekstrom A.M., Held M., Hansson L.E., et al. Helicobacter pylori in gastric cancer established by CagA immunoblot as a marker of past infection. Gastroenterology 121 4 (2001) 784-791
8. Lochhead P., and El-Omar E.M. Helicobacter pylori infection and gastric cancer. Best Pract Res Clin Gastroenterol 21 2 (2007) 281-297
9. Nozaki K., Shimizu N., Ikehara Y., et al. Effect of early eradication on Helicobacter pylori-related gastric carcinogenesis in Mongolian gerbils. Cancer Sci 94 3 (2003) 235-239
10. Magari H., Shimizu Y., Inada K., et al. Inhibitory effect of etodolac, a selective cyclooxygenase-2 inhibitor, on stomach carcinogenesis in Helicobacter pylori-infected Mongolian gerbils. Biochem Biophys Res Commun 334 2 (2005) 606-612
11. Houghton J., Stoicov C., Nomura S., et al. Gastric cancer originating from bone marrow-derived cells. Science 306 5701 (2004) 1568-1571
12. Keto Y., Ebata M., and Okabe S. Gastric mucosal changes induced by long term infection with Helicobacter pylori in Mongolian gerbils: effects of bacteria eradication. J Physiol Paris 95 1-6 (2001) 429-436
13. Hansson L.E., Nyren O., Hsing A.W., et al. The risk of stomach cancer in patients with gastric or duodenal ulcer disease. N Engl J Med 335 4 (1996) 242-249
14. Smith M.G., Hold G.L., Tahara E., et al. Cellular and molecular aspects of gastric cancer. World J Gastroenterol 12 19 (2006) 2979-2990
15. El-Omar E.M. Role of host genes in sporadic gastric cancer. Best Pract Res Clin Gastroenterol 20 4 (2006) 675-686
16. Stoicov C., Saffari R., Cai X., et al. Molecular biology of gastric cancer: Helicobacter infection and gastric adenocarcinoma: bacterial and host factors responsible for altered growth signaling. Gene 341 (2004) 1-17
17. Tomb J.F., White O., Kerlavage A.R., et al. The complete genome sequence of the gastric pathogen Helicobacter pylori. Nature 388 6642 (1997) 539-547
18. Hatakeyama M. Oncogenic mechanisms of the Helicobacter pylori CagA protein. Nat Rev Cancer 4 9 (2004) 688-694
19. Loh J.T., Torres V.J., and Cover T.L. Regulation of Helicobacter pylori cagA expression in response to salt. Cancer Res 67 10 (2007) 4709-4715
20. Hamajima N., Naito M., Kondo T., et al. Genetic factors involved in the development of Helicobacter pylori-related gastric cancer. Cancer Sci 97 11 (2006) 1129-1138
21. Malfertheiner P., Sipponen P., Naumann M., et al. Helicobacter pylori eradication has the potential to prevent gastric cancer: a state-of-the-art critique. Am J Gastroenterol 100 9 (2005) 2100-2115
22. Shimizu N., Ikehara Y., Inada K., et al. Eradication diminishes enhancing effects of Helicobacter pylori infection on glandular stomach carcinogenesis in Mongolian gerbils. Cancer Res 60 6 (2000) 1512-1514
23. Wong B.C., Lam S.K., Wong W.M., et al. Helicobacter pylori eradication to prevent gastric cancer in a high-risk region of China: a randomized controlled trial. JAMA 291 2 (2004) 187-194
24. Kato M., Asaka M., Ono S., et al. Eradication of Helicobacter pylori for primary gastric cancer and secondary gastric cancer after endoscopic mucosal resection. J Gastroenterol 42 Suppl 17 (2007) 16-20
25. Milne A.N., Sitarz R., Carvalho R., et al. Molecular analysis of primary gastric cancer, corresponding xenografts, and 2 novel gastric carcinoma cell lines reveals novel alterations in gastric carcinogenesis. Hum Pathol 38 6 (2007) 903-913
26. Fox J.G., and Wang T.C. Inflammation, atrophy, and gastric cancer. J Clin Invest 117 1 (2007) 60-69
27. Vogiatzi P., Vindigni C., Roviello F., et al. Deciphering the underlying genetic and epigenetic events leading to gastric carcinogenesis. J Cell Physiol 211 2 (2007) 287-295
28. Correa P., Piazuelo M.B., and Camargo M.C. Etiopathogenesis of gastric cancer. Scand J Surg 95 4 (2006) 218-224
29. El-Omar E.M., Carrington M., Chow W.H., et al. Interleukin-1 polymorphisms associated with increased risk of gastric cancer. Nature 404 6776 (2000) 398-402
30. El-Omar E.M., Rabkin C.S., Gammon M.D., et al. Increased risk of noncardia gastric cancer associated with proinflammatory cytokine gene polymorphisms. Gastroenterology 124 5 (2003) 1193-1201
31. Tu S., Cui G., Takaishi S., et al. Overexpression of human interleukin-1beta in transgenic mice results in spontaneous gastric inflammation and carcinogenesis. Gastroenterology 128 4, Suppl 2 (2005) A62
32. Hou L., El-Omar E.M., Chen J., et al. Polymorphisms in Th1-type cell-mediated response genes and risk of gastric cancer. Carcinogenesis 28 1 (2007) 118-123
33. Wu M.S., Wu C.Y., Chen C.J., et al. Interleukin-10 genotypes associate with the risk of gastric carcinoma in Taiwanese Chinese. Int J Cancer 104 5 (2003) 617-623
34. Lee J.Y., Kim H.Y., Kim K.H., et al. Association of polymorphism of IL-10 and TNF-A genes with gastric cancer in Korea. Cancer Lett 225 2 (2005) 207-214
35. Nakamura K., Yashiro M., Matsuoka T., et al. A novel molecular targeting compound as K-samII/FGF-R2 phosphorylation inhibitor, Ki23057, for Scirrhous gastric cancer. Gastroenterology 131 5 (2006) 1530-1541
36. Galizia G., Lieto E., Orditura M., et al. Epidermal Growth Factor Receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg 31 7 (2007) 1458-1468
37. Pinto-de-Sousa J., David L., Almeida R., et al. C-erb B-2 expression is associated with tumor location and venous invasion and influences survival of patients with gastric carcinoma. Int J Surg Pathol 10 4 (2002) 247-256
38. Park D.I., Yun J.W., Park J.H., et al. HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 51 8 (2006) 1371-1379
39. Duff S.E., Li C., Jeziorska M., et al. Vascular endothelial growth factors C and D and lymphangiogenesis in gastrointestinal tract malignancy. Br J Cancer 89 3 (2003) 426-430
40. Nikiteas N.I., Tzanakis N., Theodoropoulos G., et al. Vascular endothelial growth factor and endoglin (CD-105) in gastric cancer. Gastric Cancer 10 1 (2007) 12-17
41. Kanai T., Konno H., Tanaka T., et al. Anti-tumor and anti-metastatic effects of human-vascular-endothelial-growth-factor-neutralizing antibody on human colon and gastric carcinoma xenotransplanted orthotopically into nude mice. Int J Cancer 77 6 (1998) 933-936
42. Shah M.A., Ramanathan R.K., Ilson D.H., et al. Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma. J Clin Oncol 24 33 (2006) 5201-5206
43. Shah M.A. Irinotecan, Cisplatin, and Bevacizumab in treating patients with unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma (2004), National Library of Medicine, Bethesda (MD). Available at: http://clinicaltrials.gov/ct2/show/NCT00084604?term=bevacizumab+and+gast ric&rank=1 Accessed February 22, 2008
44. Lassen U. Avastin and Tarceva for upper gastrointestinal cancers (2006), National Library of Medicine, Bethseda (MD). Available at: http://clinicaltrials.gov/ct2/show/NCT00350753?term=bevacizumab+and+gast ric&rank=6
45. Cunningham D. Combination chemotherapy with or without Bevacizumab in treating patients with previously untreated stomach cancer or gastroesophageal junction cancer that can ce removed by surgery (2007), National Library of Medicine, Bethseda (MD). Available at: http://clinicaltrials.gov/ct2/show/NCT00450203?term=bevacizumab+and+gast ric&rank=7
46. Enzinger P. Docetaxel, Cisplatin, Irinotecan and Bevacizumab (TPCA) in metastatic esophageal and gastric cancer (2006), National Library of Medicine, Bethseda (MD). Available at: http://clinicaltrials.gov/ct2/show/NCT00394433?term=bevacizumab+and+gast ric&rank=2
47. Jhawer M. Combination chemotherapy and Bevacizumab in treating patients with recurrent, unresectable, or metastatic gastric cancer, gastroesophageal junction cancer, or esophageal cancer (2006), National Library of Medicine, Bethseda (MD). Available at: http://clinicaltrials.gov/ct2/show/NCT00403468?term=bevacizumab+and+gast ric&rank=3
48. Hynes N.E., and Lane H.A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer 5 5 (2005) 341-354
49. Becker J.C., Muller-Tidow C., Serve H., et al. Role of receptor tyrosine kinases in gastric cancer: new targets for a selective therapy. World J Gastroenterol 12 21 (2006) 3297-3305
50. Watson S.A., Grabowska A.M., El-Zaatari M., et al. Gastrin-active participant or bystander in gastric carcinogenesis?. Nat Rev Cancer 6 12 (2006) 936-946
51. Henwood M., Clarke P.A., Smith A.M., et al. Expression of gastrin in developing gastric adenocarcinoma. Br J Surg 88 4 (2001) 564-568
52. Kanda N., Seno H., Kawada M., et al. Involvement of cyclooxygenase-2 in gastric mucosal hypertrophy in gastrin transgenic mice. Am J Physiol Gastrointest Liver Physiol 290 3 (2006) G519-G527
53. Friis-Hansen L., Rieneck K., Nilsson H.O., et al. Gastric inflammation, metaplasia, and tumor development in gastrin-deficient mice. Gastroenterology 131 1 (2006) 246-258
54. Ajani J.A., Randolph Hecht J., Ho L., et al. An open-label, multinational, multicenter study of G17DT vaccination combined with cisplatin and 5-fluorouracil in patients with untreated, advanced gastric or gastroesophageal cancer: the GC4 study. Cancer 106 9 (2006) 1908-1916
55. Gilliam A.D., Watson S.A., Henwood M., et al. A phase II study of G17DT in gastric carcinoma. Eur J Surg Oncol 30 5 (2004) 536-543
56. Coussens L.M., and Werb Z. Inflammation and cancer. Nature 420 6917 (2002) 860-867
57. Jackson L., and Evers B.M. Chronic inflammation and pathogenesis of GI and pancreatic cancers. Cancer Treat Res 130 (2006) 39-65
58. Touati E., Michel V., Thiberge J.M., et al. Chronic Helicobacter pylori infections induce gastric mutations in mice. Gastroenterology 124 5 (2003) 1408-1419
59. Yasui W., Sentani K., Motoshita J., et al. Molecular pathobiology of gastric cancer. Scand J Surg 95 4 (2006) 225-231
60. Kang G.H., Lee S., Kim J.S., et al. Profile of aberrant CpG island methylation along the multistep pathway of gastric carcinogenesis. Lab Invest 83 5 (2003) 635-641
61. Oue N., Mitani Y., Motoshita J., et al. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer 106 6 (2006) 1250-1259
62. Perri F., Cotugno R., Piepoli A., et al. Aberrant DNA methylation in non-neoplastic gastric mucosa of H. pylori infected patients and effect of eradication. Am J Gastroenterol 102 7 (2007) 1361-1371
63. Maekita T., Nakazawa K., Mihara M., et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 12 3 Pt 1 (2006) 989-995
64. Ushijima T., Nakajima T., and Maekita T. DNA methylation as a marker for the past and future. J Gastroenterol 41 5 (2006) 401-407
65. Kantarjian H., Issa J.P., Rosenfeld C.S., et al. Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study. Cancer 106 8 (2006) 1794-1803
66. Kantarjian H., Oki Y., Garcia-Manero G., et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 109 1 (2007) 52-57
67. Zhang X., Yashiro M., Ohira M., et al. Synergic antiproliferative effect of DNA methyltransferase inhibitor in combination with anticancer drugs in gastric carcinoma. Cancer Sci 97 9 (2006) 938-944
68. Mitani Y., Oue N., Hamai Y., et al. Histone H3 acetylation is associated with reduced p21(WAF1/CIP1) expression by gastric carcinoma. J Pathol 205 1 (2005) 65-73
69. Yasui W., Oue N., Aung P.P., et al. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric Cancer 8 2 (2005) 86-94
70. Park J.H., Jung Y., Kim T.Y., et al. Class I histone deacetylase-selective novel synthetic inhibitors potently inhibit human tumor proliferation. Clin Cancer Res 10 15 (2004) 5271-5281
71. Suzuki T., Yokozaki H., Kuniyasu H., et al. Effect of trichostatin A on cell growth and expression of cell cycle- and apoptosis-related molecules in human gastric and oral carcinoma cell lines. Int J Cancer 88 6 (2000) 992-997
72. Huang C., Ida H., Ito K., et al. Contribution of reactivated RUNX3 to inhibition of gastric cancer cell growth following suberoylanilide hydroxamic acid (vorinostat) treatment. Biochem Pharmacol 73 7 (2007) 990-1000
73. Bokemeyer C. Phase II study with Catumaxomab in patients with gastric cancer after neoadjuvant CTx and curative resection (2007), National Library of Medicine, Bethseda (MD). Available at: http://clinicaltrials.gov/ct2/show/NCT00464893?term=removab&rank=1
74. Exelixis. Study of XL880 in subjects with gastric cancer (2006), National Library of Medicine, Bethseda (MD). Available from: http://clinicaltrials.gov/ct2/show/NCT00415480?term=XL880&rank=2
75. Montemurro F., Valabrega G., and Aglietta M. Lapatinib: a dual inhibitor of EGFR and HER2 tyrosine kinase activity. Biol Ther 7 2 (2007) 257-268